STOCK TITAN

Virpax Pharmaceuticals, Inc. - VRPX STOCK NEWS

Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.

Virpax Pharmaceuticals, Inc. (symbol: VRPX) is a pioneering biopharmaceutical company dedicated to developing advanced drug delivery systems aimed at improving patient compliance and achieving therapeutic efficacy. Specializing in non-opioid pain management, Virpax is committed to enhancing patients' quality of life through innovative pharmaceutical products.

As a preclinical stage company, Virpax focuses on creating branded pharmaceutical products for pain management. Their impressive product portfolio includes:

  • Topical Metered-Dose Spray: A novel approach for localized pain relief.
  • Liposomal in Hydrogel Encapsulation: A cutting-edge technology designed to enhance drug delivery and efficacy.
  • Enkephalin Intranasal Spray: An innovative treatment method aimed at providing rapid pain relief.

Virpax Pharmaceuticals collaborates with a network of U.S. and global partners to advance the development of its proprietary drug platforms. Their goal is to become a global leader in non-opioid pain management, creating value for investors and partners alike.

Recent achievements and current projects highlight Virpax’s commitment to innovation. These include advancing their drug candidates through preclinical stages, securing strategic partnerships, and working towards regulatory approvals.

Financially, Virpax Pharmaceuticals is focused on sustainable growth, leveraging cutting-edge technology to develop products that meet the unmet needs of pain management patients. The company’s strategic initiatives are designed to enhance shareholder value while pushing the boundaries of pharmaceutical advancements.

Stay tuned for the latest updates and exciting developments from Virpax Pharmaceuticals as they continue to make strides in the biopharmaceutical industry.

Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the approval of a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement. The reverse split ratio will be between 1-to-2 to 1-to-20, with the effective date to be announced later if the minimum bid price requirement is not met by April 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary
Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) received a notice from Nasdaq stating non-compliance with filing its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023. The company filed a Notification of Late Filing on Form 12b-25 and continues to evaluate a litigation decision. Virpax is working diligently to finalize and file the Quarterly Report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the resignation of CEO and Chairman Anthony P. Mack due to ongoing litigation. The Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has extensive experience in commercial operations and pharmaceutical sales, while Dr. Floyd brings over 25 years of experience in regulatory affairs and quality assurance. The company aims to begin first-in-human trials under the new leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
management
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced financial results for Q3 2023 and recent developments. The company shared positive preclinical study results for Probudur, its lead product candidate for post-operative pain, and plans to file an IND for Envelta, a non-addictive pain product candidate, in mid-2024. Virpax also extended its CRADA with the USAISR and appointed a new President and CEO for Novvae Pharmaceuticals. The company's Q3 2023 financial results showed a decrease in general and administrative expenses and research and development expenses compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
-
Rhea-AI Summary
Virpax Pharmaceuticals expects to submit an Investigational New Drug Application (IND) for Envelta in mid-2024, allowing clinical trials to begin. Envelta is a non-addictive pain product candidate for acute and chronic pain. It utilizes a novel intranasal drug delivery system called Molecular Envelope Technology (MET) to bypass the blood-brain barrier. Preclinical studies in rats and dogs have shown positive efficacy with minimal adverse effects. Virpax plans to advance Envelta through preclinical development and conduct first-in-human trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals extends CRADA with U.S. Army Institute of Surgical Research for Probudur
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
Rhea-AI Summary
Gerald W. Bruce appointed as President and CEO of Novvae Pharmaceuticals, Virpax's subsidiary focused on OTC pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals announces positive results for two pre-clinical Probudur dose escalation studies, showing three times longer efficacy than Exparel in the first study and four to five times longer effect in the second study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals will be presenting at the 16th annual Main Event on Tuesday, October 3rd at 12:00 PM PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
Rhea-AI Summary
Altasciences chosen by Virpax Pharmaceuticals to conduct preclinical studies for their nanoparticle AnQlar™, which aims to prevent the spread of COVID-19 and influenza. Positive collaboration and progress reported by both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none

FAQ

What does Virpax Pharmaceuticals, Inc. specialize in?

Virpax specializes in developing advanced drug delivery systems for pain management, focusing on non-opioid therapies.

What are some of Virpax Pharmaceuticals' key products?

Key products include a topical metered-dose spray, liposomal in hydrogel encapsulation, and an enkephalin intranasal spray.

Is Virpax Pharmaceuticals a preclinical stage company?

Yes, Virpax Pharmaceuticals is currently a preclinical stage biopharmaceutical company.

What is Virpax's goal in the pharmaceutical industry?

Virpax aims to become a global leader in non-opioid pain management by developing innovative pharmaceutical products.

How does Virpax enhance the efficacy of its products?

Virpax uses cutting-edge technology in its drug delivery systems to improve patient compliance and therapeutic efficacy.

Who does Virpax collaborate with for its developments?

Virpax collaborates with a network of U.S. and global partners to advance its proprietary drug platforms.

What type of spray is included in Virpax's product portfolio?

Virpax's product portfolio includes a topical metered-dose spray and an enkephalin intranasal spray.

How is Virpax Pharmaceuticals enhancing shareholder value?

Virpax focuses on sustainable growth and strategic initiatives to enhance shareholder value while advancing pharmaceutical innovations.

What technology does Virpax use for drug encapsulation?

Virpax uses liposomal in hydrogel encapsulation technology for enhanced drug delivery and efficacy.

Where can I find the latest news about Virpax Pharmaceuticals?

The latest news and updates on Virpax Pharmaceuticals can be found on financial news websites and the company's official announcements.

Virpax Pharmaceuticals, Inc.

Nasdaq:VRPX

VRPX Rankings

VRPX Stock Data

3.73M
2.84M
10.99%
0.07%
1.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERWYN